

Appl. No. 09/533,798
Amdt. dated October 28, 2005
Substitute Amendment under 37 CFR 1.116 Expedited
Procedure Examining Group 1648

PATENT

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-8 (Canceled)

9. (Currently amended) ~~A vaccine composition comprising~~ The method according to claim 12, wherein said immunizing is with a non-human, mammalian 5T4 antigen as an immunizing agent, and a pharmaceutically acceptable carrier.

10. (Currently amended) ~~The vaccine composition method according to claim 9, wherein said agent further comprising comprises~~ one or more adjuvants.

11. (Currently amended) ~~The vaccine composition method according to claim 9, wherein the non-human, mammalian 5T4 antigen is [[a]] modified to differ from a naturally occurring mammalian 5T4 antigen, and comprises comprising~~ a peptide epitope of a mammalian 5T4 antigen, and wherein said the modified 5T4 antigen induces a CTL response.

12. (Currently amended) ~~A method for eliciting an anti-tumor immunotherapeutic response to a tumor in a subject, comprising immunizing the subject with a mammalian 5T4 antigen, wherein the 5T4 antigen induces an anti-tumor immunotherapeutic response to a tumor in the subject.~~

13. (Canceled)

14. (Currently amended) ~~The method according to claim 12, wherein the 5T4 antigen is [[a]] modified to differ from a naturally occurring mammalian 5T4 antigen and comprises comprising~~ an HLA CTL peptide epitope of a mammalian 5T4 antigen, and wherein said anti-tumor immunotherapeutic response comprises a CTL response.

Appl. No. 09/533,798
Amdt. dated October 28, 2005
Substitute Amendment under 37 CFR 1.116 Expedited
Procedure Examining Group 1648

PATENT

15. (Canceled)

16. (Previously presented) The method according to claim 12, wherein the anti-tumor immunotherapeutic response comprises an antibody response.

17-45. (Canceled)

46. (Currently amended) ~~An anti-tumor immunotherapeutic vaccine composition, comprising~~ The method according to claim 12, wherein said immunizing is with a modified 5T4 antigen modified to differ from a naturally occurring mammalian 5T4 antigen and a pharmaceutically acceptable carrier, wherein ~~said the~~ modified 5T4 antigen comprises an HLA CTL peptide epitope of ~~unmodified a mammalian~~ 5T4 antigen.

47. (Currently amended) The ~~vaccine composition~~ method according to claim 46, wherein said ~~modified~~ naturally occurring mammalian 5T4 antigen is a human modified 5T4 antigen.

48. (Currently amended) The ~~vaccine composition~~ method according to ~~claim 9~~ claim 12, wherein said ~~non-human 5T4 antigen is~~ immunizing is with a murine 5T4 antigen.

49. (Currently amended) The ~~vaccine composition~~ method according to ~~claim 9~~ claim 12, wherein said ~~non-human 5T4 antigen is~~ immunizing is with a canine 5T4 antigen.

50-51. (Canceled)

52. (Currently amended) The method according to claim 12, wherein the 5T4 antigen is ~~[[a]]~~ modified to differ from a naturally occurring mammalian 5T4 antigen.

53. (New) The method of claim 12, wherein said immunizing is with a human 5T4 antigen.